poisar

Stock

Pharming Group N.V. ADS, each representing 10 PHAR

$11.72-5.10%

Overview

PHAR market data

Price History

PHAR price chart

Valuation & Profitability

Provider-backed
P/E (TTM)
88.15
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
$0.00
Diluted earnings per share over the trailing twelve months.
Beta
0.36
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
2.5%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$0.83 – $1.82
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $710.6M · P/B 4.06 · P/S 2.24.

Company News

7 captured
Pharming Group shares are trading higher after the company announced the commercial launch of Joenja in Japan for adult and pediatric patients with activated PI3K delta syndrome aged 4 years and older.Benzinga · Aug 13, 2026, 7:06 PM
Pharming Launches Joenja (Leniolisib) in Japan for APDS Patients Aged 4 and Older, Marking First Global Launch for Children 4 To 11Benzinga · Aug 13, 2026, 5:07 AM
Canaccord Genuity Maintains Buy on Pharming, Raises Price Target to $38Benzinga · Aug 3, 2026, 9:28 PM
Pharming shares are trading lower after the company reported Q2 financial results and lowered its FY26 sales guidance below analyst estimates.Benzinga · Jul 30, 2026, 5:26 PM
Meta Posts Mixed Q2 Results, Joins Coursera, Qualcomm And Other Big Stocks Moving Lower In Thursday’s Pre-Market SessionBenzinga · Jul 30, 2026, 12:02 PM
Pharming Lowers FY2026 Sales Guidance from $405.000M-$425.000M to $375.000M-$395.000M vs $419.100M EstBenzinga · Jul 30, 2026, 7:48 AM
Pharming Q2 EPS $0.02, Inline, Sales $90.200M Miss $100.625M EstimateBenzinga · Jul 30, 2026, 5:07 AM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock